{
    "root": "35ba2cc7-d1ab-5e85-e063-6394a90a1cd0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Glimepiride",
    "value": "20250522",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "GLIMEPIRIDE",
            "code": "6KY687524K",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5383"
        }
    ],
    "indications": {
        "text": "glimepiride tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus [ ( 14.1 ) ] . limitations glimepiride tablets used treatment type 1 diabetes mellitus diabetic ketoacidosis , would effective settings .",
        "doid_entities": [
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes mellitus (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "type 1 diabetes mellitus (DOID:9744)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9744"
            },
            {
                "text": "diabetic ketoacidosis (DOID:1837)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1837"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended starting dose 1 2 mg daily . increase 1 2 mg increments frequently every 1-2 weeks based glycemic response . maximum recommended dose 8 mg daily . ( 2.1 ) administer breakfast first meal day . ( 2.1 ) 1 mg starting dose titrate slowly patients increased risk hypoglycemia ( e.g . , elderly , patients renal impairment ) . ( 2.1 )",
        "doid_entities": [
            {
                "text": "hypoglycemia (DOID:9993)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9993"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "glimepiride tablets usp available following strengths package sizes : \u2022 4 mg ( white capsule shaped flat-faced , bevelled edged tablets breakline sides debossed ' ' ' 4 ' either side breakline one side ) ndc 60760-845-90 bottles 90 store 20\u00b0c- 25\u00b0c ( 68\u00b0 - 77\u00b0f ) [ usp controlled room temperature ] dispense well-closed containers safety closures .",
    "adverseReactions": "glimepiride tablets contraindicated patients history hypersensitivity reaction : glimepiride product 's ingredients [ ( 5.2 ) ] . sulfonamide derivatives : patients developed allergic reaction sulfonamide derivatives may develop allergic reaction glimepiride tablets.do glimepiride tablets patients history allergic reaction sulfonamide derivatives .",
    "indications_original": "Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [\n \n  see Clinical Studies (\n  \n   14.1)\n \n  ]. \n  \n                     Limitations of Use\n                       Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.",
    "contraindications_original": "Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1-2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily. ( 2.1 ) Administer with breakfast or first meal of the day. ( 2.1 ) Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment). ( 2.1 )",
    "warningsAndPrecautions_original": "Glimepiride tablets USP are available in the following strengths and package sizes:\n  \n\u2022     4 mg (White capsule shaped flat-faced, bevelled edged tablets with breakline on both sides and debossed with 'I' and '4' on either side of breakline        only on one side)\n  \n                  \n                  NDC 60760-845-90 BOTTLES OF 90\n                  \n                     \nStore at 20\u00b0C- 25\u00b0C (68\u00b0 - 77\u00b0F) [See USP Controlled Room Temperature]\n  \nDispense in well-closed containers with safety closures.",
    "adverseReactions_original": "Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to:\n                  \n                     Glimepiride or any of the product's ingredients [\n  \n   see Warnings and Precautions (\n   \n    5.2)\n  \n   ].\n \n  \n                     Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets.Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives.",
    "drug": [
        {
            "name": "Glimepiride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5383"
        }
    ]
}